Your browser doesn't support javascript.
loading
GLP-1 RAs and SGLT2-Is to Lower Glucose and Reduce the Risk of Cardiovascular and Diabetic Kidney Disease.
Morrison, Leigh; Gabison, Jonathan; Oshman, Lauren.
Afiliación
  • Morrison L; From the Clinical Assistant Professor, Department of Family Medicine, University of Michigan (LM, JG); Associate Professor, Department of Family Medicine, University of Michigan (LO). morrisol@med.umich.edu.
  • Gabison J; From the Clinical Assistant Professor, Department of Family Medicine, University of Michigan (LM, JG); Associate Professor, Department of Family Medicine, University of Michigan (LO).
  • Oshman L; From the Clinical Assistant Professor, Department of Family Medicine, University of Michigan (LM, JG); Associate Professor, Department of Family Medicine, University of Michigan (LO).
J Am Board Fam Med ; 37(3): 372-382, 2024.
Article en En | MEDLINE | ID: mdl-39142859
ABSTRACT
The landscape of diabetes management has changed, such that the goal of pharmacotherapy extends beyond glucose-lowering to prioritize risk reduction of cardiovascular disease and diabetic kidney disease. Two newer classes of medications, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2-Is), have become first line therapies for many patients with type 2 diabetes to reduce cardiovascular and renal complications of type 2 diabetes. This review article will describe the mechanism of action, evidence for cardiovascular and kidney outcomes, contraindications, adverse effects, and risk mitigation strategies for the GLP-1 RA and SGLT2-I drug classes. In addition, we will provide a practical approach for primary care clinicians to prescribe, adjust, and combine these medication classes, while considering patient preference, tolerability, comorbidities, cost, and availability.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Diabetes Mellitus Tipo 2 / Nefropatías Diabéticas / Receptor del Péptido 1 Similar al Glucagón / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Hipoglucemiantes Límite: Humans Idioma: En Revista: J Am Board Fam Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Diabetes Mellitus Tipo 2 / Nefropatías Diabéticas / Receptor del Péptido 1 Similar al Glucagón / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Hipoglucemiantes Límite: Humans Idioma: En Revista: J Am Board Fam Med Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos